TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sino Biopharmaceutical ( (HK:1177) ) has shared an update.
Sino Biopharmaceutical Limited has announced the successful enrollment of the first patient in the Phase I clinical trial for TRD208, a first-in-class, non-opioid, multi-target, multi-modal analgesic developed by the company. TRD208 is expected to revolutionize acute pain management by blocking multiple pain-related pathways and offering peripheral anti-inflammatory effects, potentially replacing current combination therapies. This development underscores the company’s commitment to addressing unmet clinical needs and improving patient compliance while avoiding opioid-related risks.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the development and marketing of innovative non-opioid targeted drugs, particularly in the field of analgesia. The company has established a diversified portfolio of marketed products, including Meloxicam Injection, Flurbiprofen Cataplasms, and Lidocaine Cataplasms, among others.
YTD Price Performance: 123.38%
Average Trading Volume: 103,641,403
Technical Sentiment Signal: Buy
Current Market Cap: HK$126.1B
Learn more about 1177 stock on TipRanks’ Stock Analysis page.